维生素D3对危重症骨转换标志物的影响:VITdAL-ICU研究的事后分析
本文为VITdAL-ICU随机双盲安慰剂对照试验的事后分析,纳入289例25-羟基维生素D≤20 ng/ml的危重症成人幸存者,比较负荷剂量540,000 IU后每月90,000 IU共5次的高剂量维生素D3与安慰剂对骨转换标志物β-Crosslaps(CTX)和骨钙素(OC)的影响。结果显示两组CTX和OC随时间显著变化(p<0.001),但组间无差异(p=0.688和p=0.972),骨密度、跌倒和骨折也无差异。作者认为维生素D补充对骨转换标志物无显著影响,需进一步研究。
要点
- 危重症成人25-羟基维生素D≤20 ng/ml者,高剂量维生素D3对CTX和OC无显著组间差异。
- 两组CTX和OC随时间显著变化(p<0.001),6个月后均恢复正常。
- 骨密度、跌倒和骨折在两组间无差异。
核心结论
- 维生素D补充对骨转换标志物无显著影响。
- 需进一步研究评估维生素D对ICU幸存者肌肉骨骼结局的有效性。
研究设计与样本
- VITdAL-ICU研究为随机、双盲、安慰剂对照试验,纳入25-羟基维生素D≤20 ng/ml的危重症成人。
- 本分析纳入289例幸存者(209例电话随访,80例个人随访)。
- 干预为高剂量维生素D3:负荷剂量540,000 IU,负荷剂量后1个月开始每月90,000 IU共5次维持剂量;对照为安慰剂。
- 骨转换标志物于第0、3、7、28和180天检测;6个月后测量骨密度;评估自报跌倒和骨折。
主要发现
- 基线时CTX升高、OC降低,6个月后两组均恢复正常。
- 两组间骨转换标志物、骨密度、跌倒或骨折均无差异。
- 线性混合效应模型中,CTX和OC随时间显著变化(p<0.001),但维生素D组与安慰剂组无差异(p=0.688和p=0.972)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In this post hoc analysis of the VITdAL-ICU study, an RCT in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml, vitamin D3 did not have a significant effect on β-Crosslaps and osteocalcin. INTRODUCTION: Observational studies have shown accelerated bone loss in ICU survivors. A reversible contributor is vitamin D deficiency. In a post hoc analysis of the VITdAL-ICU study, we evaluated the effect of high-dose vitamin D3 on the bone turnover markers (BTM) β-Crosslaps (CTX) and osteocalcin (OC). METHODS: The VITdAL-ICU study was a randomized, double-blind, placebo-controlled trial in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml who received placebo or high-dose vitamin D3 (a loading dose of 540,000 IU and starting 1 month after the loading dose five monthly maintenance doses of 90,000 IU). In this analysis on 289 survivors (209 telephone, 80 personal follow-up visits), BTM were analyzed on days 0, 3, 7, 28, and 180; self-reported falls and fractures were assessed. Bone mineral density (BMD) was measured after 6 months. RESULTS: At baseline, CTX was elevated; OC was low in both groups-after 6 months, both had returned to normal. There were no differences between groups concerning BTM, BMD, falls, or fractures. In linear mixed effects models, CTX and OC showed a significant change over time (p < 0.001, respectively), but there was no difference between the vitamin D and placebo group (p = 0.688 and p = 0.972, respectively). CONCLUSIONS: Vitamin D supplementation did not have a significant effect on BTM. Further studies should assess the effectiveness of vitamin D on musculoskeletal outcomes in ICU survivors.
引用
- Schwetz V, Schnedl C, Urbanic-Purkart T, et al. Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study. Osteoporos Int. 2017. PMID: 28842727. doi:10.1007/s00198-017-4190-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。